학술논문
Efficacy and safety of upadacitinib maintenance therapy for moderately to severely active ulcerative colitis in patients responding to 8 week induction therapy (U-ACHIEVE Maintenance): overall results from the randomised, placebo-controlled, double-blind, phase 3 maintenance study
Document Type
Article
Author
Source
In: The Lancet Gastroenterology and Hepatology . (The Lancet Gastroenterology and Hepatology, November 2023, 8(11):976-989)
Subject
Language
English
ISSN
24681253